Underuse of beta-blockers in patients with heart failure and COPD

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/27213
• EU PAS number:
  EUPAS11387
• Study ID:
  27213
• Official title and acronym:
  Underuse of beta-blockers in patients with heart failure and COPD
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Cardiovascular comorbidity is common in chronic obstructive pulmonary disease (COPD). Retrospective cohort studies have shown putative benefits of beta-blockers in COPD. Although beta-blockers are established therapy in heart failure (HF) guidelines, including for patients with COPD, there remain concerns regarding bronchoconstriction even with cardioselective beta-blockers. We aim to assess the real life use of beta-blockers for patients with HF who also have COPD.
• Study status:
  Finalised

Research institution and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Actual: 15/06/2015

Study start date

Actual: 26/06/2015

Date of final study report

Planned: 20/11/2015

Actual: 23/11/2016

Sources of funding

Other

More details on funding

RiRL

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable